Prognosis of decompensated heart failure patients with preserved systolic function is predicted by NT-proBNP variations during hospitalization

International Journal of Cardiology

Volumn 117, Issue 1, 2007, Pages 75-79

  Bettencourt, Paulo ^a   Azevedo, Ana ^a   Fonseca, Luísa ^a   Araújo, José P ^a   Ferreira, Susana ^a   Almeida, Rui ^a   Rocha Goncalves, Francisco ^a   Ferreira, António ^a  

^a University of Porto   (Portugal)

Author keywords

Heart failure; Natriuretic peptides; NT proBNP; Preserved systolic function; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HEMOGLOBIN; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEMOGLOBIN DETERMINATION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; SEX DIFFERENCE; SYSTOLE;

AGED; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PATIENT READMISSION; PEPTIDE FRAGMENTS; PORTUGAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; SYSTOLE; VENTRICULAR FUNCTION;

EID: 33947139106     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.06.004     Document Type: Article

References (22)

1. Hogg K., Swedberg K., and McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43 (2004) 317-327
2. Berry C., Hogg K., Norrie J., Stevenson K., Brett M., and McMurray J. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 91 (2005) 907-913
3. Bettencourt P., Ferreira A., Dias P., Castro A., Martins L., and Cerqueira-Gomes M. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology 93 (2000) 19-25
4. Maisel A.M., Krishnaswamy P., Nowak R., et al. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
5. Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal ProBNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (2005) 948-954
6. Hobbs F.D., Davis R.C., Roalfe A.K., Hare R., Davies M.K., and Kenkre J.E. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 324 (2002) 1498
7. Dias P., Rodrigues R.A., Queiros M.C., et al. Prognosis in patients with heart failure and preserved left ventricular systolic function. Rev Port Cardiol 20 (2001) 1223-1232
8. Anderson B., and Hall C. N-terminal proatrial natriuretic peptide and prognosis in patients with heart failure and preserved systolic function. J Card Fail 6 (2000) 208-213
9. Remme W.J., and Swedberg K. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 1527-1560
10. Tsutamoto T., Atsuyuki W., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentrations in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997) 509-516
11. Bettencourt P., Ferreira A., Dias P., et al. Predictors of prognosis in mild to moderate heart failure. J Card Fail 6 (2000) 306-313
12. Gardner R.S., Ozalo F., Murday A.J., Robb S.D., and McDonaght T.A. N terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24 (2003) 1735-1743
13. Valle R., Aspromonte N., Feola M., et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 11 (2005) 498-503
14. Kirk V., Bay M., Parner J., et al. N-terminal proBNP and mortality in hospitalased patients with heart failure and preserved vs reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 6 (2004) 335-341
15. Cheng V., Kazanegra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37 (2001) 386-391
16. Bettencourt P., Ferreira S., Azevedo A., and Ferreira A. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med 113 (2002) 215-219
17. Bettencourt P., Azevedo A., Pimenta J., Frioes F., Ferreira S., and Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004) 2168-2174
18. Latini R., Masson S., Anand I., et al. Valsartan heart failure trial investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the valsartan heart failure trial. Circulation 106 (2002) 2454-2458
19. Bettencourt P., Friões F., Azevedo A., et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol 93 (2004) 45-48
20. Murdoch D.R., McDonagh T.A., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138 (1999) 1126-1132
21. Troughton R., Lainchbury J., Doughty R., and Wright S. Guiding and monitoring heart failure therapy with NT-proBNP: concepts and clinical studies. J Card Fail 11 (2005) 34-37
22. Takeda Y., Fukutomi T., Suzuki S., et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 94 (2004) 448-453